RT Journal Article
T1 Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain.
T2 Antipsicóticos inyectables de liberación prolongada para el tratamiento de la esquizofrenia en España.
A1 Arango, Celso
A1 Baeza, Inmaculada
A1 Bernardo, Miquel
A1 Cañas, Fernando
A1 de Dios, Consuelo
A1 Díaz-Marsá, Marina
A1 García-Portilla, María Paz
A1 Gutiérrez-Rojas, Luis
A1 Olivares, José Manuel
A1 Rico-Villademoros, Fernando
A1 Rodríguez-Jiménez, Roberto
A1 Sánchez-Morla, Eva María
A1 Segarra, Rafael
A1 Crespo-Facorro, Benedicto
K1 Antipsicóticos
K1 Antipsychotics
K1 Depot
K1 Drug utilization
K1 Esquizofrenia
K1 Inyectables de liberación prolongada
K1 Long-acting injectable
K1 Schizophrenia
K1 Utilización de medicamentos
AB Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting injectable formulations (LAI) arose to improve adherence with the associated potential of reducing the risk of relapse. The objective of this article is to analyze the use of LAI antipsychotics in Spain, which is similar to other European countries but with a predominance of the use of second generation LAI, to discuss the possible causes of prescribing differences with respect to other countries (including organizational aspects, attitudes of psychiatrists, patients and family members, and clinical practice guidelines), and to discuss their use in acute psychiatric units, first episode, and in children and adolescents. In our view, while it is necessary to increase existing evidence regarding the advantages of LAI antipsychotics and the differentiation between LAI antipsychotics currently available, their use will likely continue to grow driven by clinical experience.
YR 2018
FD 2018-06-25
LK http://hdl.handle.net/10668/12655
UL http://hdl.handle.net/10668/12655
LA en
LA es
DS RISalud
RD Apr 17, 2025